After witnessing a sharp dip of 10.63 per cent to Rs 933.10 on the BSE in intra-day trade, shares of Sun Pharma finally ended at Rs 951.60, down 8.86 per cent.
At the NSE, the stock settled 8.77 per cent lower at Rs 952.20.
Led by the sharp decline in the stock, the company's market valuation dipped by Rs 22,262.25 crore to Rs 2,28,960.75 crore.
Japanese drug maker Daiichi Sankyo today sold its entire stake of around 9 per cent in Sun Pharmaceutical Industries for over Rs 20,420 crore, which it received after merger of Ranbaxy in the Indian firm, ending seven years of its tumultuous experience in the country.
The company, which had forayed into the growing Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, sold over 21 crore shares in Sun Pharma.
In a statement issued today, Daiichi said, "The sale of Sun Pharma shares has been completed."
At the average share price of about Rs 950 in the morning trade when Daiichi announced selling its stake, the value of its shares is estimated to be Rs 20,420 crore.
Last month, Sun Pharma had announced completion of merger of Ranbaxy with itself, almost a year after announcing the USD 4-billion deal.
As per Forbes, which ranks people on the basis of their wealth, Dilip Shanghvi, the founder and managing director of Sun Pharma was the biggest loser today with USD 1.8 billion dip in his net worth to USD 20.3 billion.
Sun Pharmaceutical Industries chief Dilip Shanghvi has recently beaten Mukesh Ambani to the top spot in Forbes' richest Indians list.
Meanwhile, in the stock market the BSE benchmark Sensex ended the day with a loss of 210.17 points at 27,676.04.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
